Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2030

Study Completion Date

December 1, 2030

Conditions
Large B-cell LymphomaRelapse
Interventions
DRUG

Epcoritamab

"Epcoritamab will be administered via subcutaneous injection at the following dose levels and schedule over a total of twelve cycles:~* Cycle 1 Day 1: Step-up dose of 0.16 mg~* Cycle 1 Day 8: Step-up dose of 0.80 mg~* Cycle 1 Day 15: First full dose of 48 mg.~* Cycles 2 through 4 Days 1, 8 and 15: 48 mg~* Cycles 5 through 12 Days 1 and 15: 48 mg"

DRUG

Loncastuximab Tesirine

"Loncastuximab will be administered intravenously (IV) at the following dose level and schedule over a total of four cycles:~* Cycles 1 and 2 Day 1: 120 mcg/kg~* Cycles 3 and 4 Day 1: 75 mcg/kg~* Cycle 4 Day 22: 75 mcg/kg"

Trial Locations (1)

33136

University of Miami, Miami

Sponsors
All Listed Sponsors
collaborator

ADC Therapeutics S.A.

INDUSTRY

collaborator

Genmab

INDUSTRY

lead

University of Miami

OTHER